Does Neffy Work Safely for Anaphylaxis?
Neffy, an FDA-approved nasal spray version of epinephrine (brand name for the active ingredient in EpiPens), treats severe allergic reactions like anaphylaxis. Approved in 2024, it delivers 2 mg epinephrine per spray for adults and adolescents over 30 kg, or 1 mg for kids 15-30 kg. Clinical trials showed it raises blood epinephrine levels comparably to injections, resolving symptoms in most cases within minutes.[1][2]
What Do Safety Studies Show?
Trials with over 600 participants confirmed Neffy matches IM epinephrine's pharmacokinetics, with peak levels in 5-20 minutes and bioavailability around 80%. No serious adverse events linked to efficacy failure occurred. Common side effects mirror epinephrine: nasal discomfort (15-20%), headache, throat irritation, or mild hypertension—typically mild and short-lived.[1][3]
How Does Neffy Compare to EpiPen Safety?
Both have identical active ingredients and side effect profiles, but Neffy avoids needles, reducing injury risk. EpiPen data from decades of use shows anaphylaxis recurrence in 10-20% of cases regardless of delivery, not a Neffy-specific issue. Neffy's nasal route may cause less systemic absorption variability in some users.[2][4]
What Side Effects Are Patients Reporting?
Real-world feedback notes nasal burning or runny nose in 10-25% of first uses, fading quickly. Rare risks include rapid heartbeat or tremors, same as injections. No increased anaphylaxis mortality or severe events in post-approval monitoring.3
Can Neffy Be Used in Special Cases?
Safe for most with type 1 allergies, but avoid if narrow-angle glaucoma, certain heart conditions, or recent MAOI use—standard epinephrine warnings. Not studied in kids under 15 kg or unconscious patients; IM injection preferred there. Pregnancy category B, used if benefits outweigh risks.[1][2]
When Might Neffy Not Be Safe?
Overdose risk low due to single-spray design, but repeat doses every 5 minutes if needed, max 2-3. Improper storage (above 77°F) degrades it faster than EpiPens. Allergic reactions to excipients (e.g., benzalkonium chloride) possible but rare.4
[1]: FDA Approval Letter for NEFFY (nFDA.gov, Aug 2024)
[2]: ARS Pharma Phase 3 Trials (NEFFY.com/clinical-data)
[3]: Neffy Prescribing Information (ARSPharma.com)
[4]: Journal of Allergy and Clinical Immunology (2024 comparison study)